Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11961352 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL1487007 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL765807 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL8520973 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL11961353 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL345858 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL366852 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL3974543 | 1.00 | L3MBTL1 (0.33) | L3MBTL1CA2 | |
| SCHEMBL16730247 | 0.84 | CA2 (0.32) | CA2 | |
| SCHEMBL3016063 | 0.84 | CA2 (0.32) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3255043-B1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2021-01-20 | — | — | EP | disclosed |
| US-9975881-B2 | Compound | ASTRAZENECA AB (SE) | 2018-05-22 | — | — | US | disclosed |
| EP-3141235-A1 | N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3-METHYLAZETIDINE-L -SULFONAMIDE | IP Gesellschaft für Management mbH (DE) | 2017-03-15 | — | — | EP | disclosed |
| EP-2740458-B1 | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | IP GES FÜR MAN MBH (DE) | 2016-08-03 | — | — | EP | disclosed |
| US-20160108023-A1 | Novel Compound | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | disclosed |
| US-9221782-B2 | Compound | ASTRAZENECA AB (SE) | 2015-12-29 | — | — | US | disclosed |
| US-20140235606-A1 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | ASTRAZENECA AB (SE) | 2014-08-21 | — | — | US | disclosed |
| US-20140228339-A1 | Novel Compound | ASTRAZENECA AB (SE) | 2014-08-14 | — | — | US | disclosed |
| EP-2740458-A1 | Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide | IP Gesellschaft für Management mbH (DE) | 2014-06-11 | — | — | EP | disclosed |
| US-8748603-B2 | Crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]THIO]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide | ASTRAZENECA AB (SE) | 2014-06-10 | — | — | US | disclosed |
| US-8735413-B2 | Compound | ASTRAZENECA AB (SE) | 2014-05-27 | — | — | US | disclosed |
| EP-2731945-A1 | N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | AstraZeneca AB (SE) | 2014-05-21 | — | — | EP | disclosed |
| EP-2593448-A1 | NEW CRISTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENY)METHYL)THIO]-6-{[(1R,2S)-2,3- DIHYDROXY-1-METHYLPROPYL]OXY}-4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | AstraZeneca AB (SE) | 2013-05-22 | — | — | EP | disclosed |
| US-20130040926-A1 | NOVEL COMPOUND | ASTRAZENECA UK LIMITED | 2013-02-14 | — | — | US | disclosed |
| WO-2013008002-A1 | N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013008002-A1 | N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR | ASTRAZENECA AB (SE) | 2013-01-17 | — | — | WO | disclosed |
| US-20120202287-A1 | Stem Cell Culture Methods | ITI SCOTLAND LIMITED (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20120015927-A1 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | US | disclosed |
| WO-2012007748-A1 | NEW CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENY)METHYL)THIO]-6-{[(1R,2S)-2,3-DIHYDROXY-1- METHYLPROPYL]OXY}-4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | ASTRAZENECA AB (SE) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228339-A1 | Novel Compound | CXCR2, CXCR1, CCR5 | L3MBTL1 4863/4885CA2 2395/4885 |
| US-20130040926-A1 | NOVEL COMPOUND | CXCR2, CXCR1, CCR5 | L3MBTL1 4863/4885CA2 2395/4885 |
| US-20160108023-A1 | Novel Compound | CXCR2, CXCR1, CCR5 | L3MBTL1 4863/4885CA2 2395/4885 |
| US-20120015927-A1 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | CXCR1, CXCR2, CCR2 | L3MBTL1 4565/4885CA2 207/4885 |
| US-20120202287-A1 | Stem Cell Culture Methods | KIT, SOX18, MCL1 | L3MBTL1 4573/4885CA2 1970/4885 |
| US-20140235606-A1 | CRYSTALLINE FORMS OF N-[2-[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6--4-PYRIMIDINYL]-1-AZETIDINESULFONAMIDE | CXCR1, CXCR2, CCR2 | L3MBTL1 4607/4885CA2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.